# INTEGRATED BIOPHARMA INC

INTEGRATED BIOPHARMA INC is a public company headquartered in Hillside, NJ, United States.

## Company overview

- **Legal name:** INTEGRATED BIOPHARMA INC
- **Former names in filing history:** INTEGRATED HEALTH TECHNOLOGIES INC (2002-09-12 to 2003-04-16); CHEM INTERNATIONAL INC (1996-12-09 to 2002-05-14)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Hillside, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** June 30
- **SEC CIK:** 0001016504

## About

Integrated BioPharma manufactures, markets and distributes vitamins, nutritional supplements and herbal products. Manhattan Drug Company operates its contract-manufacturing business, supplying distributors, multilevel marketers and specialized healthcare providers. Other operations include warehousing and fulfillment through MDC Warehousing and Distribution and raw-material distribution through Chem International. Its operating model centers on supplement production and related services. Its reported principal executive office is in Hillside, NJ (United States). For fiscal 2026, ended 2026-06-30, its originally reported results included revenue of USD 43,872,000; a net loss of USD 2,842,000; cash provided by operations of USD 1,241,000. At that year-end, it reported total assets of USD 25,338,000 and cash and cash equivalents of USD 4,471,000. Historical figures retain the originally filed amounts where later comparative figures differ.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2026 (period ended 2026-06-30)

- **Revenue:** $43.9M (USD 43,872,000)
- **Net income:** -$2.8M (USD -2,842,000)
- **Total assets:** $25.3M (USD 25,338,000)
- **Cash and equivalents:** $4.5M (USD 4,471,000)
- **Operating cash flow:** $1.2M (USD 1,241,000)

### FY2025 (period ended 2025-06-30)

- **Revenue:** $54.4M (USD 54,353,000)
- **Net income:** $808,000 (USD 808,000)
- **Total assets:** $24.9M (USD 24,901,000)
- **Cash and equivalents:** $3.6M (USD 3,615,000)
- **Operating cash flow:** $2.1M (USD 2,065,000)

### FY2024 (period ended 2024-06-30)

- **Revenue:** $50.3M (USD 50,317,000)
- **Net income:** $112,000 (USD 112,000)
- **Total assets:** $26.2M (USD 26,207,000)
- **Cash and equivalents:** $1.7M (USD 1,677,000)
- **Operating cash flow:** $943,000 (USD 943,000)

### FY2023 (period ended 2023-06-30)

- **Revenue:** $50.7M (USD 50,672,000)
- **Net income:** -$34,000 (USD -34,000)
- **Total assets:** $25.4M (USD 25,431,000)
- **Cash and equivalents:** $1.3M (USD 1,316,000)
- **Operating cash flow:** $1.2M (USD 1,232,000)
- **Later filings:** Total assets: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-09-25 — period 2026-09-25 — FORM 8-K
- Form 10-K — filed 2026-09-25 — period 2026-06-30 — FORM 10-K
- Form 8-K — filed 2026-08-20 — period 2026-08-20 — FORM 8-K
- Form 8-K — filed 2026-07-02 — period 2026-06-30 — FORM 8-K PNC FIRST AMENDMENT
- Form 8-K — filed 2026-05-08 — period 2026-05-08 — FORM 8-K
- Form 10-Q — filed 2026-05-08 — period 2026-03-31 — FORM 10-Q
- Form 8-K — filed 2026-04-15 — period 2026-04-14 — FORM 8-K
- Form 8-K — filed 2026-02-18 — period 2026-02-17 — FORM 8-K
- Form 8-K — filed 2026-02-11 — period 2026-02-11 — FORM 8-K
- Form 10-Q — filed 2026-02-11 — period 2025-12-31 — FORM 10-Q
- Form 8-K — filed 2025-12-01 — period 2025-12-01 — FORM 8-K
- Form 8-K — filed 2025-11-10 — period 2025-11-10 — FORM 8-K

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/integrated-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology